Abstract
Gastrointestinal (GI) disturbances in Parkinson's disease (PD) are varied, involve the upper and lower GI tract and are evident in all stages of the disease. Recognition and re-evaluation of these non motor symptoms (NMS) due to the course of PD is important. They have a major impact on the efficacy of oral anti-parkinsonian medication and health related quality of life. Treatment needs to be tailored to the specific patient case with evaluation of PD stage, the specific GI NMS and comorbidities. This article provides an overview of the pharmacological and non-pharmacological therapeutic options for GI NMS in PD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
